Recombinant human FSH and recombinant human LH in a 2:1 ratio combination: a new tool for ovulation induction

Hypogonadotrophic hypogonadism is a dysfunction characterized by the lack of gonadotrophin production and, therefore, attenuated or stopped gonadal action, which leads to anovulation and subsequent infertility. A new fixed combination of recombinant human FSH and recombinant human LH in a 2:1 ratio has recently been developed. Pharmacological studies show bioequivalence with the parameters of the separated compounds. Phase II/III studies have demonstrated high efficiency and safety for inducing ovulation in these patients. Studies analyzing the potential role of recombinant human luteinizing hormone supplement in normovulatory patients following ovarian stimulation for IVF–embryo transfer under pituitary downregulation, suggest a benefit in patients over 35 years old and/or with low response to stimulation with recombinant human follicle-stimulating hormone administered alone. However, further studies are needed to further analyze this issue.